HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Students’ OTC Cough/Cold Drug Abuse Steady, Monitoring Survey Says

This article was originally published in The Tan Sheet

Executive Summary

Results of the latest national survey of students' illicit drug use show no change in the prevalence of young people abusing OTC cough and cold medicines, and the head researcher says "there is little evidence yet of much improvement" in preventing misuse

You may also be interested in...



“Troubling” DXM Abuse Numbers Underscore Need For Education – CHPA

The Consumer Healthcare Products Association says the "troubling trend" of OTC cough medicine abuse shown in results of a nationwide survey released Jan. 10 is "evidence of the importance" of prevention efforts by it and other groups

Door Opened On Revising Labeling For Teens, But FDA Not Anxious To Enter

FDA executives and researchers are recommending the agency and the drug industry improve drug labels so younger consumers can understand how to safely and effectively use the products. However, some experts say revised labels will not stop adolescents who want to abuse OTC drugs

Biden DXM Bill Includes Age Limit, Bulk Ingredient Scheduling

The Consumer Healthcare Products Association backs Sen. Joe Biden's proposal to set a nationwide age limit on purchases of dextromethorphan-containing OTC drugs, but the group differs with the bill's approach to regulating bulk sales of raw DXM

Related Content

Topics

UsernamePublicRestriction

Register

RS137921

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel